Hemorrhage Countermeasure Evaluation Capabilities RFI

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEF ADVANCED RESEARCH PROJECTS AGCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

DARPA-SN-26-61

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AC12

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents2
The Defense Advanced Research Projects Agency (DARPA), through its Biological Technologies Office (BTO), has issued a Special Notice (Procurement Identifier: DARPA-SN-26-61) seeking information from qualified industry and academic organizations regarding their capabilities to support the evaluation and commercialization of hemorrhage countermeasures. This Request for Information (RFI) is a preliminary market research effort intended to identify potential partners who can provide comprehensive, independent verification and validation, clinical trial management, and commercialization support for products designed to mitigate hemorrhage. The primary objective of this procurement activity is to ensure that promising hemorrhage countermeasures—developed through DARPA’s research, development, testing, and evaluation (RDT&E) initiatives—are rigorously assessed for safety and efficacy by third-party entities. Furthermore, DARPA aims to facilitate the successful transition of these technologies from the laboratory to both civilian and government markets. To achieve this, the agency is particularly interested in respondents capable of addressing all three task domains: independent verification and validation, clinical trial execution, and commercialization strategy development. The intent is to engage a single provider with comprehensive oversight of the data, thereby enhancing efficiency and enabling tailored regulatory and market entry strategies. Key requirements for interested parties include demonstrated expertise in conducting independent assessments of biomedical products, managing clinical trials in compliance with regulatory standards, and developing commercialization pathways for medical countermeasures. Respondents should be prepared to support the transition of products beyond the RDT&E phase, ensuring readiness for both regulatory approval and market adoption. This notice is classified under NAICS Code 541714 (Research and Development in Biotechnology, except Nanobiotechnology), with Product Service Code AC12. The contracting entity is the Defense Advanced Research Projects Agency (DARPA), a federal office within the Department of Defense. The primary point of contact for this opportunity is Lt. Cmdr. Robert Murray, who can be reached via email at [email protected]. As this is an RFI, it is not a solicitation for proposals but rather an information-gathering exercise to inform future procurement strategies. There are no set-aside requirements or special considerations specified at this stage. Interested organizations are encouraged to review the full notice and attachments available on SAM.gov (Opportunity ID: caac77d5137c44588121195fee48f74a) and submit their responses by May 4, 2026. This opportunity is particularly relevant for entities with established capabilities in biotechnology research and development, clinical trial management, and commercialization of medical technologies, especially those with experience in transitioning products to both government and civilian healthcare markets.